Latest Oxaliplatin Stories
QUEBEC CITY, June 29 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
Data Reported at ASCO Confirm a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm Versus Placebo + Capecitabine Arm QUEBEC CITY, June 8 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
NEW YORK, June 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
CALGARY, May 19 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following submission to the U.S. Food and Drug Administration (FDA) for review, the Company is initiating a U.S.
SOUTH SAN FRANCISCO, Calif., May 10 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc.
WASHINGTON, April 19 /PRNewswire-USNewswire/ -- Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented data at the American Association for Cancer Research's 101st Annual Meeting 2010 that shows when genistein, a component of soy, is paired with the FDA-approved drug oxaliplatin, pancreatic cancer cells become more sensitive to chemotherapy. (Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO) The title of the poster presentation is, "Genistein...
Phase 3 X-PECT Trial (Xeloda(R)) + Perifosine Evaluation in Colorectal Cancer Treatment) being conducted by partner Keryx Biopharmaceuticals pursuant to Special Protocol Assessment with the Food and Drug Administration QUEBEC CITY, April 8 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
NEW YORK, April 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., April 5 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc.
NEW YORK, April 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the U.S.
- A gift; a largess; a gratuity; a present; a dole.